TheEdgeResearch
Home / Stocks / IMMG

Immage Biotherapeutics Corp. (IMMG)

OTC Financial Services Financial - Conglomerates
$0.00 ▲ +0.00%
Market Cap
$15,174
Sector
Financial Services
Industry
Financial - Conglomerates
Beta
32.51
52-Wk Range
0.000001-0.0001
CEO
Zhi Cong Mou
Country
US
Currency
USD

Immage Biotherapeutics Corp. operates in the Financial - Conglomerates industry of the Financial Services sector, headquartered in Bethesda, MD, US. The stock last traded at $0.00, up 0.00% on the session, giving a market capitalisation of $15,174. On trailing twelve-month figures it carries a trailing P/E of -0.07, a net margin of 0.0%. Its beta of 32.51 implies it has historically moved more than the broad market.

Valuation & profitability (TTM)
P/E
-0.07
Price / Sales
0.00
Price / Book
0.08
EV / EBITDA
0.62
Gross margin
0.0%
Operating margin
0.0%
Net margin
0.0%
Return on equity
Debt / equity
0.28
Current ratio
3.67
Dividend yield
0.0%
Payout ratio
0.0%
Company profile
Exchange
Other OTC
Employees
3
IPO date
2022-12-02
Headquarters
Bethesda, MD, US
About Immage Biotherapeutics Corp.

Presently, Immage Biotherapeutics Corp. lacks substantial business operations. Historically, its endeavors centered on the creation of cutting-edge immunotherapy biologics designed to combat diverse cancer types across the United States. Established in 2012, the entity was initially known as Epicure Charcoal, Inc., rebranding to Immage Biotherapeutics Corp. in June 2015. Its corporate headquarters are situated in Bethesda, Maryland, and it operates as a subsidiary of Coventry International Limited.

Comparable companies

Immage Biotherapeutics Corp. is most often compared with the following Financial Services names:

AXTGBITCFBLPFFCHFICIVXEURIRNBITLGNWNCGXYNH
More research on IMMG
IMMG technical analysis IMMG TheEdge Score Compare against peers
Open full interactive analysis & DCF →